



FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Dr. Roscoe Moore, Jr., Former US Assistant Surgeon General to its Scientific Advisory Board

Dover, Delaware, September 11, 2022 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Roscoe Moore, Jr. has joined its Scientific Advisory Board.

Dr. Moore is a highly esteemed public health expert who brings over four decades of experience to Immgenuity. His track record in public health is globally recognized, having served as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC), and as an Assistant United States Surgeon General for five administrations. He has also served as a Senior Epidemiologist for the United States Department of Health and Human Services (HHS), and as the Chief Medical Officer of the United States Department of Agriculture's (USDA) Food Safety and Inspection Service.

As a member of Immgenuity's Scientific Advisory Board, Dr. Moore will provide valuable insights into public health, epidemiology, and therapeutic strategies. He will also offer guidance on the development of Immgenuity's groundbreaking technology, which is designed to provide a remission strategy by restoring immune signaling and overcoming immune escape of HIV.

“We are thrilled to have Dr. Moore join our Scientific Advisory Board. As a member of Immgenuity's Scientific Advisory Board, Dr. Moore will provide valuable insights into public health, epidemiology, and therapeutic strategies. He will also offer guidance on the development of Immgenuity's groundbreaking technology, which is designed to provide a remission strategy by restoring immune signaling and overcoming immune escape of HIV”, said Immgenuity's CEO, Sateesh Apte, MD.”

Dr. Moore added, “I am enthusiastic about joining Immgenuity's Scientific Advisory Board and look forward to working with the team to help advance their mission of addressing HIV reservoirs. The technology that Immgenuity is developing has the potential to revolutionize the way we treat HIV, and I am proud to be a part of it.”

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.